PET and MRI Imaging of Brain Tumors Using [18F]PARPi

Pilot Study of [18F]PARPi PET/MR Imaging in Patients With New and/or Suspected Recurrent Brain Tumors

Status

Completed

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04173104

Enrollment

Registered

2019-11-21

Start date

2019-11-01

Completion date

2026-02-05

Last updated

2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Cancer, Brain Tumor

Keywords

Brain cancer, 18FPARPi, PET scan, MRI, Memorial Sloan Kettering Cancer Center, 19-311

Brief summary

This study is to collect data about how 18FPARPi can be used together with PET/positron emission tomography and MRI/magnetic resonance imaging scans to take pictures of brain cancer

Interventions

DIAGNOSTIC_TESTPET/MR with [18F]PARPi

One PET/MR study (with up to 3 scan times) with \[18F\]PARPi

DRUG[18F]PARPi

Injection of \<100ug of \[18F\]PARPi prior to 1 PET/MR

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with new or suspected recurrent brain tumors (including suspected recurrent brain tumors showing growth from any preceding scan) * Age \>/= 18 years * Minimum at least one brain lesion size \>/= 1.5cm diameter * Scheduled to undergo treatment at MSK * Willingness to sign informed consent * Able to receive intravenous gadolinium contrast per MSK Department of Radiology guidelines

Exclusion criteria

* Any contraindication to 3T MRI (PET/MR scanner is 4.0 Tesla) * Pregnancy or breast-feeding women

Design outcomes

Primary

Measure	Time frame	Description
SUVmax measurements	Up to 24 weeks	\[18F\]PARPi updtake in lesions will be quantified by standard SUVmax measurements from PET/MR scans

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORRobert Young, MD

Memorial Sloan Kettering Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026